ANI Transforms With Novitium And Sandoz Deals
Company On Track To File Corticotropin sNDA By End Of Q2
US generics player ANI Pharmaceutical is looking to file a supplemental new drug application of corticotropin gel with the FDA, with the company seeing the Cortrophin product as a “transformational opportunity.” The company also expects to close its acquisition of Novitium in the second half of 2021, anticipating over 25 product launches.
